CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 204 enrolled
Drug / intervention
Ruxolitinib Cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05755438
NCT05755438Phase 3Completed
CompareCT.gov

A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis

Incyte Corporation·interventional·Posted Mar 6, 2023·Updated Nov 14, 2025

In Brief

A Phase 3 clinical trial evaluating Ruxolitinib Cream and Vehicle Cream for Prurigo. Completed, enrolled 204 participants across 71 sites in 11 countries.

Detailed Summary

The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrurigo
CountriesArgentina, Belgium, Canada, Chile, France, Germany, Italy, Netherlands, Poland, Spain, United States
Collaborators--

Timeline

Phase 3CompletedFinished
202420252026
First PostedMar 6, 2023
Enrollment StartMar 10, 2023
Primary CompletionOct 7, 2024
Study CompletionAug 13, 2025
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 3.3 years ago

Interventions

Ruxolitinib Creamdrug

Ruxolitinib cream 1.5% twice daily (BID) during the vehicle controlled (DBVC)and open label treatment period (OLE).

Vehicle Creamdrug

Ruxolitinib matching vehicle cream 1.5% twice daily (BID) during the vehicle controlled period (DBVC).